| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 02/28/2002 | WO2002016319A1 Novel thiourea compounds and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016318A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016315A1 Aza-amino acid derivatives (factor xa-inhibitors 15) |
| 02/28/2002 | WO2002016313A2 Integrin receptor inhibitors |
| 02/28/2002 | WO2002016311A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 02/28/2002 | WO2002015943A2 Novel radiotherapeutic formulations containing 224ra and a method for their production |
| 02/28/2002 | WO2002015923A1 Orally administered peptides to ameliorate atherosclerosis |
| 02/28/2002 | WO2002015922A2 New uses for amino acid anticonvulsants for treatment of pain |
| 02/28/2002 | WO2002015917A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 02/28/2002 | WO2002015916A1 Use of dihydroboswellic acids or hydrogenated extracts of boswellia for prophylactic and/or therapeutic treatment |
| 02/28/2002 | WO2002015913A1 Treatment of trauma, and other indications |
| 02/28/2002 | WO2002015888A1 Drug-release controlling system |
| 02/28/2002 | WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015884A2 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015879A1 A method of treating a systemic disease |
| 02/28/2002 | WO2002015878A1 Aqueous suspension preparations |
| 02/28/2002 | WO2002015846A2 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/28/2002 | WO2002009667A9 Dispersions for formulating slightly or poorly soluble active ingredients |
| 02/28/2002 | WO2001087887A3 Neuroprotective and anti-proliferative compounds |
| 02/28/2002 | WO2001087234A3 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079162A3 INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| 02/28/2002 | WO2001077377A8 Diagnosis of diseases associated with dna replication by assessing dna methylation |
| 02/28/2002 | WO2001076530A3 Il-8 receptor antagonists |
| 02/28/2002 | WO2001072281A3 Microspheres for active embolization |
| 02/28/2002 | WO2001070984A3 Anti-tissue factor antibodies with enhanced anticoagulant potency |
| 02/28/2002 | WO2001070720A3 Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| 02/28/2002 | WO2001068852A3 Apolipoprotein-a-i regulation of t-cell signalling |
| 02/28/2002 | WO2001068845A3 Inflammation-inducible hybrid promoters, vectors containing same and uses thereof |
| 02/28/2002 | WO2001064639A3 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 02/28/2002 | WO2001046200A8 Novel piperidine and piperazine derivatives |
| 02/28/2002 | WO2001045714A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001045661A3 Cosmetic and/or pharmaceutical preparations |
| 02/28/2002 | WO2001042462A3 Phospholipase a2 inhibitory peptides from python reticulatus |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001031029A3 Human sphingosine kinase gene |
| 02/28/2002 | WO2001027254A3 Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy |
| 02/28/2002 | WO2001017614A3 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 02/28/2002 | WO2001005422A3 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | WO2000067746A8 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/28/2002 | US20020026056 Substituted imidazoles having cytokine inhibitory activity |
| 02/28/2002 | US20020026050 Thrombin receptor antagonists |
| 02/28/2002 | US20020026034 3-aminoethyl-n-amidino-2,5-dihydropyrrole derivatives having arginine mimetic properties |
| 02/28/2002 | US20020025985 Apoptosis inhibitor |
| 02/28/2002 | US20020025983 Anticoagulant mixture; cardiovascular disordrs; premenstrual disorders; bone disorders |
| 02/28/2002 | US20020025957 Anticoagulants, cardiovascular disorders |
| 02/28/2002 | US20020025935 Antiinflammatory agents; autoimmune diseases; central nervous system disorders |
| 02/28/2002 | US20020025923 Antiinflammatory agents |
| 02/28/2002 | US20020025348 Treatment for inflammatory bowel disease (IBD) and related conditions |
| 02/28/2002 | US20020025317 For therapy and prophylaxis of pathological condition associated with expression of Interelukin-12 and/or Interleukin-18, including excessive or inappropriate amounts of those cytokines |
| 02/28/2002 | US20020025304 Novel interferon for the treatment of multiple sclerosis |
| 02/28/2002 | DE10040105A1 Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften Peptide and peptidomimetic derivatives having integrin inhibitor properties |
| 02/28/2002 | CA2740815A1 New uses for amino acid anticonvulsants |
| 02/28/2002 | CA2425206A1 Treatment of trauma, and other indications |
| 02/28/2002 | CA2421062A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/28/2002 | CA2420283A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 02/28/2002 | CA2420233A1 Method for identifying substances useful for treating inflammation using the response element to the i.kappa.b.alpha. ror receptor |
| 02/28/2002 | CA2420190A1 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2420179A1 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | CA2420071A1 Process for the preparation of neutrophil inhibitory factor |
| 02/28/2002 | CA2420024A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | CA2419872A1 Identification of a human n-terminal acetyltransferase gene |
| 02/28/2002 | CA2419592A1 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2419580A1 Integrin receptor inhibitors |
| 02/28/2002 | CA2418730A1 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2417507A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 02/28/2002 | CA2415838A1 Aza-amino acid derivatives (factor xa-inhibitors 15) |
| 02/28/2002 | CA2411924A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting proteinkinases |
| 02/27/2002 | EP1182200A1 Tricyclic fused heterocycle compounds, process for preparing the same and use thereof |
| 02/27/2002 | EP1182193A1 Remedies for neuropathic pain |
| 02/27/2002 | EP1182192A1 4-hydroxypiperidine derivatives having antiarrhythmic effect |
| 02/27/2002 | EP1181390A1 27 human secreted proteins |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181381A2 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181318A2 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181315A1 LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
| 02/27/2002 | EP1181303A1 50 human secreted proteins |
| 02/27/2002 | EP1181285A2 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181284A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 02/27/2002 | EP1181282A2 Benzothiazinone and benzoxazinone compounds |
| 02/27/2002 | EP1181278A1 Cyclic amine derivatives and their uses |
| 02/27/2002 | EP1181276A1 Morpholino-n-ethyl ester derivative of an indole spla-2 inhibitor |
| 02/27/2002 | EP1181266A1 Squaric acid derivatives as cell adhesion molecules |
| 02/27/2002 | EP1181054A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| 02/27/2002 | EP1181052A1 Protein a based binding domains with desirable activities |
| 02/27/2002 | EP1181047A2 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 02/27/2002 | EP1181035A2 Substantially oil-free cyclosporin compositions |
| 02/27/2002 | EP1181031A1 Novel antiangiogenic peptides |
| 02/27/2002 | EP1181030A2 Tanacetum parthenium extract |
| 02/27/2002 | EP1181021A1 Novel, specific inhibitors of acute and chronic inflammation |
| 02/27/2002 | EP1181019A1 Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome |
| 02/27/2002 | EP1181017A1 Metalloprotease inhibitors |
| 02/27/2002 | EP1181010A1 Pharmaceutical chewing gum formulations |
| 02/27/2002 | EP0946156B1 Drinkable ibuprofen composition |
| 02/27/2002 | EP0939623B1 Oral delayed immediate release formulation and method of preparation therefor |